Nordic Nanovector consolidates senior leadership team and restructures to conserve resources as it explores strategic options
Oslo, Norway, 26 August 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces that further to the decisions to discontinue the PARADIGME study for its lead asset Betalutin[®], restructure the company and appoint Carnegie Investment Bank to explore strategic options the senior leadership team will be consolidated, and current Chief Executive Officer Erik Skullerud will transition out of his role. Nordic Nanovector’s Chief Financial Officer Malene Brondberg will assume the combined position of CFO and interim CEO while the Company continues to